Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- New IDF DM Management GL Stresses Importance of Postprandial Glucose
November 19, 2007
- Education on Vaccination for Uterine Cervical Cancer Needed
November 19, 2007
- All Antidepressants to Warn of Risk of Suicide in Patients Aged 24 or Younger
November 12, 2007
- Former Tanabe Seiyaku: Remicade Drives Sales, Profits
November 12, 2007
- Concerta Approved for ADHD, Depression Deleted as Indication for Ritalin
November 12, 2007
- Eisai: Record-High Sales, Profits Driven by Aricept
November 12, 2007
- JMA Calls For Reimbursement of Generics Used Off-label
November 12, 2007
- Debiopharm Licenses DACH-platin MediCelle from NanoCarrier
November 12, 2007
- Sawai Revises Business Forecasts Downward
November 12, 2007
- Taisho Concludes LOI with Pfizer on TS-032
November 12, 2007
- Different Views Presented on NHI Price Listing for Generics 4 Times a Year
November 12, 2007
- About 80% of Intestinal Flora Species Remain Unknown
November 12, 2007
- Korosho to Promote Elimination of Films from Imaging Diagnosis
November 12, 2007
- 11 Generics Receive NHI Price Listing in the 1st Biannual Listing
November 12, 2007
- Pfizer Japan Begins Restructuring to Spur Simultaneous Global Development
November 12, 2007
- MEDICAL DEVICE NEWS IN BRIEF
November 12, 2007
- BUSINESS NEWS IN BRIEF
November 12, 2007
- STPO PRESS／Prasugrel Significantly Reduces Risk of Serious CV Events Compared to Clopidogrel
November 12, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 12, 2007
- TOPICS 2 articles
November 12, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…